Mack T. Ruffin IV, M.D., M.P.H.

Professor Emeritus
Professor and Chair, Department of Family and Community Medicine at Penn State Hershey Medical Center.

Department of Family Medicine
University of Michigan Medical School
1018 Fuller St.
Ann Arbor, Michigan 48104-1213

Michigan Experts Profile

Administrative Contact

Jill Bowdler, (734) 998-7120 x316, jbowdler@med.umich.edu

Biography

Dr. Ruffin's research involves cancer prevention via primary and secondary strategies, chemoprevention and cancer screening. He is unique in the fact that he is an academic family medicine physician who has held two consecutive five-year K24 mentor awards from NIH as well as having numerous other projects funded through the CDC and NCI. He is also a leader of a health disparity center in collaboration with investigators at The Ohio State University focused on Appalachian women’s health.

Dr. Ruffin is active in organizational and volunteer activities, institutionally, nationally and internationally. He is a member of the Michigan Cancer Consortium, and serves on several study section and journal editorial boards. He has published more than 100 articles and has been an invited speaker at over 40 venues.

He is a productive, well-respected member of the Department of Family Medicine, who is invested in the research of changing patient and physician practices relative to cancer prevention.

 

Areas of Interest

Research Interests
  • Cancer prevention and screening
  • Nutrition
  • Health promotion
Clinical Interests
  • Cancer prevention and screening
  • Orthopedics
  • Health promotion
  • Preventive Medicine
  • Sports medicine
  • Nutrition

Credentials

Medical School
  • M.D., Medical College of Virginia, Richmond, Va., 1984
Residency
  • Bowman Gray School of Medicine/Baptist Hospital, Family Medicine, Winston-Salem, N.C., 1987
Advanced Degree
  • M.P.H., Epidemiology, University of Minnesota, Minneapolis, Minn., 1989
Fellowship
  • Family Medicine Fellowship, Academic Medicine and Clinical Investigation, Department of Family Practice and Community Health, University of Minnesota, Minneapolis, Minn., 1989
Board Certification
  • Family Medicine

Grants

Current Research
  • Reducing Cervical Cancer in Appalachia, NIH/NCI, Co-Investigator (PI: Paskett)
  • Great Lakes/New England Clinical Epidemiology and Validation Center, NIH/NCI, Co-Investigator (PI: Brenner)
  • Decision Aid to Technologically Enhance Shared Decision Making (DATES), NIH/NCI, Co-Investigator (PI: Jimbo)

Published Articles or Reviews

Key Publications
  1. Nie S, Lo A, Wu J, Zhu J, Tan Z, Simeone DM, Anderson MA, Shedden KA, Ruffin MT, Lubman DM. Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. J Proteome Res, 2014;13(4):1873-84.
  2. de la Cruz MD, Young AP, Ruffin, MT IV. Diagnosis and management of pancreatic cancer. Am Fam Physician, 2014;89(8):626-32.
  3. Ruffin MT 4th, Shultz CG. Screening and prevention in primary care. Prim Care, 2014;41(2):xvii-xviii.
  4. Turgeon DK, Ruffin MT 4th. Screening strategies for colorectal cancer in asymptomatic adults. Prim Care, 2014;41(2):331-3.
  5. Ruffin M. Combined HPV and cytology better than cytology for protection against cervical cancer. Evid Based Med, 2014;19(4):148. 
Full List of Publications
  1. Ruffin MT, Hunter RE, Arendt EA. Exercise and secondary amenorrhea linked through endogenous opioids. Sports Med, 1990;10(2):65-71.
  2. Ruffin MT. Fibrolamellar hepatoma. Am J Gastroenterol, 1990;85(5):577-81.
  3. Ruffin MT, Van Noord GR. Improving the yield of endocervical elements in a Pap smear with the use of the cytology brush. Fam Med, 1991;23(5):365-9.
  4. Klinkman MS, Zazove P, Mehr DR, Ruffin MT. A criterion-based review of preventive health care in the elderly. Part 1. Theoretical framework and development of criteria. J Fam Pract, 1992;34(2):205-24.
  5. Zazove P, Mehr DR, Ruffin MT, Klinkman MS, Peggs JF, Davies TC. A criterion-based review of preventive health care in the elderly. Part 2. A geriatric health maintenance program. J Fam Pract, 1992;34(3):320-47.
  6. Ruffin MT, Kantor R. Adults' knowledge about the use of child restraint devices. Fam Med, 1992;24(5):382-5.
  7. Bland CJ, Ruffin MT. Characteristics of a productive research environment: Literature review. Acad Med, 1992;67(6):385-97.
  8. Ruffin MT, Sheets KJ. Primary care research funding sources. J Fam Pract, 1992;35(3):281-7.
  9. Ruffin MT, Kiningham RB. Anterior knee pain: The challenge of patellofemoral syndrome. Am Fam Phys, 1993;47(1):185-94.
  10. Green LA, Ruffin MT. Differences in management of suspected myocardial infarction in men and women. J Fam Pract, 1993;36(4):389-93.
  11. Smith MA, Ruffin MT, Lee LA. The rational management of labor. Am Fam Phys, 1993;47(6):1471-81.
  12. Reed BD, Zazove P, Gregoire L, Gorenflo DW, Lancaster WD, Ruffin MT. Factors associated with human papillomavirus infection in women encountered in community-based offices. Arch Fam Med, 1993;2(12):1239-48.
  13. Zazove P, Reed BD, Gregoire L, Gorenflo DW, Lancaster WD, Ruffin MT, Hruszczyk J. Presence of human papillomavirus infection of the uterine cervix as determined by different detection methods in a low-risk community-based population. Arch Fam Med, 1993;2(12):1250-8.
  14. Ruffin MT, August DA, Kelloff GJ, Boone CW, Weber BL, Brenner DE. Selection criteria for breast cancer chemoprevention subjects. J Cell Biochem, 1993;17G(Suppl):231-41.
  15. Elward KS, Goldstein AO, Ruffin MT. Fellowship training in Family Medicine: Results of a national survey. Fam Med, 1994;26(6):376-81.
  16. Rifat SF, Ruffin MT. Management of thyroid nodules. Am Fam Phys, 1994;50(4):785-90.
  17. Ruffin MT, Cohen M. Evaluation and management of fatigue. Am Fam Phys, 1994;50(3):625-34.
  18. Green LA, Ruffin MT. A closer examination of sex bias in the treatment of ischemic cardiac disease. J Fam Pract, 1994;39(4):331-6.
  19. Woloshin KK, Ruffin MT, Gorenflo DW. Patient’s interpretation of qualitative probability statements. Arch Fam Med, 1994;3(11):961-6.
  20. Gorenflo DW, Ruffin MT, Sheets KJ. A multivariate model for specialty choice by medical students. J Fam Pract, 1994;39(6):570-6.
  21. Kreher NE, Hickner JM, Ruffin MT, Lin CS. Effect of distance and travel time on rural women's compliance with screening mammography: An UPRNET Study. J Fam Pract, 1995;40(2):143-7.
  22. Rifat SF, Ruffin MT, Gorenflo DW. Disqualifying criteria in a preparticipation sports evaluation. J Fam Pract, 1995;41(1):42-50.
  23. Ruffin MT, Ogaily MS, Johnston CM, Gregoire L, Lancaster WD, Brenner DE. Surrogate endpoint biomarkers for cervical cancer chemopreventive trials. J Cell Biochem, 1995;23(Suppl):113-24.
  24. Rock CL, Saxe GA, Ruffin MT, August DA, Schottenfeld D. Carotenoids, vitamin A, and estrogen receptor status in breast cancer. Nutr Cancer, 1996;25(3):281-96.
  25. Burney KD, Krishnan K, Ruffin MT, Zhang D, Brenner DE. Adherence to single daily dose of aspirin in a chemoprevention trial: An evaluation of self-report and microelectronic monitoring. Arch Fam Med, 1996;5(5):297-300.
  26. Porter AT, Zimmerman J, Ruffin M, Chernew M, Callaghan C, Davis R, Lee F, Montie J, Swanson GM, Oesterling JE. Recommendations of the first Michigan conference on prostate cancer. Urology, 1996;48(4):519-33.
  27. Ruffin MT, Krishnan K, Rock CL, Normolle D, Vaerten MA, Peters-Golden M, Crowell J, Kelloff G, Boland CR, Brenner DE. Suppression of human colorectal mucosal prostaglandins: Determining the lowest effective dose. J Natl Cancer Inst, 1997;89(15):1152-60.
  28. Doukas DJ, Fetters M, Ruffin MT, McCullough LB. Ethical considerations in the provision of controversial screening tests. Arch Fam Med, 1997;6(5):486-90.
  29. Krishnan K, Ruffin MT, Brenner DE. Colon cancer chemoprevention: Clinical development of aspirin as a chemopreventive agent. J Cell Biochem, 1997;28-29(Suppl):148-58.
  30. Rock CL, Lovalvo JL, Emenhiser C, Ruffin MT, Flatt SW, Schwartz SJ. Bioavailability of beta-carotene is lower in raw than in processed carrots and spinach in women. J Nutr, 1998;128(5):913-6.
  31. Krishnan K, Ruffin MT, Brenner DE. Clinical models of chemoprevention for colon cancer. Hematol Oncol Clin North Am ,1998;12(5):1079-113.
  32. Ruffin MT, Lancaster WD. Clinical models of chemoprevention for cervical cancer. Hematol Oncol Clin North Am, 1998;12(5):1115-34.
  33. Reed BD, Ruffin MT, Gorenflo DW, Zazove P. The psychosexual impact of human papillomavirus cervical infections. J Fam Pract, 1999;48(2):110-6.
  34. Drewnowski A, Henderson SA, Hann CS, Barratt-Fornell A, Ruffin M. Age and food preferences influence dietary intakes of breast care patients. Health Psychol, 1999;18(6):570-8.
  35. Ruffin MT, Gorenflo DW, Woodman B. Predictors of screening for breast, cervical, colorectal, and prostatic cancer among community-based primary care practices. JABFP, 2000;13(1):1-10.
  36. Ruffin MT, Baron J. Recruiting subjects in cancer prevention and control studies. J Cell Biochem, 2000;77(S34):80-3.
  37. Rock CL, Michael CW, Reynolds RK, Ruffin MT. Prevention of cervix cancer. Crit Rev Oncol Hematol, 2000;33(3):169-85.
  38. Krishnan K, Ruffin MT, Brenner DE. Chemoprevention for colorectal cancer. Crit Rev Oncol Hematol, 2000;33(3):199-219.
  39. Drewnowski A, Herderson SA, Hann CS, Berg WA, Ruffin MT.  Genetic taste markers and preferences for vegetables and fruit of female breast care patients. J Am Diet Assoc, 2000;100(2):191-7.
  40. Ruffin MT, Rock CL. Do antioxidants still have a role in the prevention of human cancer? Curr Oncol Rep, 2001;3(4):306-13.
  41. Krishnan K, Ruffin MT, Normolle D, Shureiqi I, Burney K, Bailey J, Peters-Golden M, Rock CL, Boland CR, Brenner DE. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev, 2001;10(5):447-53.
  42. Rock CL, Moskowitz, A, Huizar B, Saenz CC, Clark JT, Daly TL, Chin H, Behling C, Ruffin MT. High vegetable and fruit diet intervention in premenopausal women with cervical intraepithelial neoplasia. J Am Diet Assoc, 2001;101(10):1167-74.
  43. Bieniasz ME, Underwood D, Bailey J, Ruffin MT. Women’s feedback on a chemopreventive trial for cervical dysplasia. Appl Nurs Res, 2003;16(1):22-8.
  44. Ruffin MT. Family physicians' knowledge of risk factors for cervical cancer. J Women’s Health, 2003;12(6):561-7.
  45. Rockwell P. Steyers, T, Ruffin MT. Chaperone use by family physicians during the collection of a Pap smear. Ann Fam Med, 2003;1(4):218-20.
  46. Bailey JM, Bieniasz ME, Kmak D, Brenner DE, Ruffin MT. Recruitment and retention of economically underserved women to a cervical cancer prevention trial. Appl Nurs Res, 2004;17(1):55-60.
  47. Holcomb B, Bailey J, Crawford K, Ruffin MT. Adults' knowledge and behaviors related to human papillomavirus infection. JABFP, 2004;17(1):26-31.
  48. Krishnan K, Aoki T, Ruffin MT, Normolle DP, Boland CR, Brenner DE. Effects of low dose aspirin (81 mg) on proliferating cell nuclear antigen and Amaranthus caudatus labeling in normal-risk and high-risk human subjects for colorectal cancer. Cancer Detect Prev, 2004;28(2):107-13.
  49. Ruffin MT, Gorenflo DW. Interventions fail to increase screening rates in community-based primary care practices. Prev Med, 2004;39(3):435-40.
  50. Fetters MD, Ivankova NV, Ruffin MT, IV, Creswell JW. Developing a web site in primary care. Fam Med, 2004;36(9):651-9.
  51. Ruffin MT, Bailey JM, Normolle DP, Michael CW, Bieniasz ME, Kmak DC, Unger ER, Brenner DE. Low dose topical delivery of all-trans Retinoic Acid for CIN II and III. Cancer Epidemiol Biomarkers Prev, 2004;13(12):2148-52.
  52. Rajeevan MS, Swan DC, Nisenbaum R, Lee DR, Vernon SD, Ruffin MT, Horowitz IR, Flowers LC, Kmak D, Tadros T, Birdsong G, Husain M, Srivastava S, Unger ER. Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Int J Cancer, 2005;115(1):114-20.
  53. Steinau M, Lee DR, Rajeevan MS, Vernon SD, Ruffin MT 4th, Unger ER. Gene expression profile of cervical tissue compared to exfoliated cells: Impact on biomarker discovery. BMC Genomics, 2005;6(1):64.
  54. Zick SM, Blume A, Normolle D, Ruffin M. Challenges in herbal research: A randomized clinical trial to assess blinding with ginger. Complement Ther Med, 2005;13(2):101-6.
  55. Normolle D, Ruffin MT IV, Brenner D. Design of early validation trials of biomarkers. Cancer Inform, 2005;1(1):25-31.
  56. Jimbo M, Nease DE, Jr., Ruffin MT, IV, Gurpreet RK. Information technology and cancer prevention. CA Cancer J Clin, 2006;56(1):26-36.
  57. Lao CD, Ruffin MT IV, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med, 2006;17(6):10.
  58. Ruffin MT 4th, Bailey JM, Roulston D, Lee DR, Tucker RA, Swan DC, Unger ER. Human papillomavirus in amniotic fluid. BMC Pregnancy Childbirth, 2006;6:28.
  59. Steinau M, Rajeevan MS, Lee DR, Ruffin MT, Horowitz IR, Flowers LC, Tadros T, Birdsong G, Husain M, Kmak DC, Longton GM, Vernon SD, Unger ER. Evaluation of RNA markers for early detection of cervical neoplasia in exfoliated cervical cells. Cancer Epidemiol Biomarkers Prev, 2007;16(2):295-301.
  60. Ruffin MT, Fetters MD, Jimbo M. Preference-based electronic decision aid to promote colorectal cancer screening: results of a randomized controlled trial. Prev Med, 2007;45(4):267-73.
  61. Qiu Y, Patwa TH, Xu L, Shedden K, Misek DE, Tuck M, Jin G, Ruffin MT, Turgeon DK, Synal S, Bresalier R, Marcon N, Brenner DE, Lubman DM. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res, 2008;7(4):1693-1703.
  62. Demark-Wahnefried W, George SL, Switzer BR, Snyder DC, Madden JF, Polascik TJ, Ruffin MT 4th, Vollmer RT. Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials, 2008;5(3):262-72.
  63. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev, 2008;17(6):1411-7.
  64. Wilkerson JE, Bailey JM, Bieniasz ME, Rock CL, Ruffin MT. Cervical cancer precursors, diet and bitter taste (6-n-propylthiouracil ‘PROP’) receptors. Open Nutr J, 2008;2:51-3.
  65. Zick SM, Djuric Z, Ruffin MT, Litzinger AJ, Normolle DP, Alrawi S, Feng MR, Brenner DE. Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev, 2008;17(8):1930-6.
  66. Paskett ED, Reeves KW, McLaughlin JM, Katz ML, McAlearney AS, Ruffin MT, Halbert CH, Merete C, Davis F, Gehlert S. Recruitment of minority and underserved populations in the United States: The Centers for Population Health & Health Disparities Experience. Contemp Clin Trials, 2008;29(6):847-61.
  67. Nease DE Jr, Ruffin MT 4th, Klinkman MS, Jimbo M, Braun TM, Underwood JM. Impact of a generalizable reminder system on colorectal cancer screening in diverse primary care practices: a report from the prompting and reminding at encounters for prevention project. Med Care, 2008;46(9 Suppl 1):S68-73.
  68. Djuric Z, Bird CE, Furumoto-Dawson A, Rauscher GH, Ruffin MT 4th, Stowe RP, Tucker KL, Masi CM. Biomarkers of psychological stress in health disparities research. Open Biomark J, 2008;1:7-19.
  69. Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT IV, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev, 2008;17(12):3577-87.
  70. Stoffel EM, Turgeon DK, Stockwell DH, Zhao L, Normolle DP, Tuck MK, Bresalier RS, Marcon NE, Baron JA, Ruffin MT, Brenner DE, Syngal S; Great Lakes-New England Clinical Epidemiology and Validation Center of the Early Detection Research Network. Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). Cancer Prev Res, 2008;1(6):470-5.
  71. Stoffel EM, Turgeon DK, Stockwell DH, Normolle DP, Tuck MK, Marcon NE, Baron JA, Bresalier RS, Arber N, Ruffin MT, Syngal S, Brenner DE; Great Lakes New England Clinical Epidemiology and Validation Center of the Early Detection Research Network. Chromoendoscopy detects more adenomas than colonoscopy using intensive inspection without dye spraying. Cancer Prev Res, 2008;1(7):507-13.
  72. Zick SM, Ruffin MT, Lee J, Normolle DP, Siden R, Alrawi S, Brenner DE. Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer, 2009;17(5):563-72.
  73. Li C, Simeone DM, Brenner DE, Anderson MA, Shedden KA, Ruffin MT, Lubman DM. Pancreatic cancer serum detection using a lectin/glyco-antibody array method. J Proteome Res, 2009;8(2)483-92.
  74. Wang C, O'Neill SM, Rothrock N, Gramling R, Sen A, Acheson LS, Rubinstein WS, Nease DE Jr, Ruffin MT 4th; for the Family Healthware™ Impact Trial (FHITr) group. Comparison of risk perceptions and beliefs across common chronic diseases. Prev Med, 2009;48(2)197-202.
  75. Ruffin MT IV, Creswell JW, Jimbo M, Fetters MD. Factors influencing choices for colorectal cancer screening among previously unscreened African and Caucasian Americans: Findings from a triangulation mixed methods investigation. J Community Health, 2009;34(2):79-89.
  76. Wilkerson JE, Bailey JM, Bieniasz ME, Murray SI, Ruffin MT. Psychosocial factors in risk of cervical intraepithelial lesions. J Womens Health (Larchmt), 2009;18(4):513-8.
  77. Patel D, Shih YJ, Newton DW, Michael CW, Oeth PA, Kane MD, Opipari AW, Ruffin MT, Kalikin LM, Kurnit DM. Development and evaluation of a PCR and mass spectroscopy-based (PCR-MS) method for quantitative, type-specific detection of human papillomavirus. J Virolog Methods, 2009;160(1-2):78-84.
  78. Dempsey AF, Abraham LM, Dalton V, Ruffin M. Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol, 2009;19(8):531–8.
  79. Katz ML, Reiter PL, Heaner S, Ruffin MT, Post DM, Paskett ED. Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia. Vaccine, 2009;27(30):3945-52.
  80. O’Neill SM, Rubinstein WS, Wang C, Yoon PW, Acheson LS, Rothrock N, Starzyk EJ, Beaumont JL, Galliher JM, Ruffin MT IV, for the Family HeathwareTM Impact Trial Group. Familial risk for common diseases in primary care: The Family HealthwareTM Impact Trial. Am J Prev Med, 2009;36(6):506-14.
  81. Reiter PL, Katz ML, Ferketich AK, Ruffin MT, Paskett ED. Appalachian self-identity among women in Ohio Appalachia. Journal of Rural Community Psychology, 2009; E12(1).
  82. Reiter PL, Katz ML, Ferketich AK, Ruffin MT, Paskett ED. Measuring cervical cancer risk: development and validation of the CARE Risky Sexual Behavior Index. Cancer Causes Control, 2009;20(10):1865-71.
  83. Paskett ED, McLaughlin JM, Reiter PL, Lehman AM, Rhoda DA, Katz ML, Hade EM, Post DM, Ruffin MT. Psychosocial predictors of adherence to risk-appropriate cervical cancer screening guidelines: A cross sectional study of women in Ohio Appalachia participating in the Community Awareness Resources and Education (CARE) project. Prev Med, 2010;50(1-2):74-80.
  84. Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine, 2010;28(4):989-95.
  85. Ruffin MT, Normolle DP, Evelegh MJ, Baron JA, Bresalier RS, Marcon NE, Syngal S, Turgeon DK, Tuck MK, Brenner DE. Rectal mucosal quantitative galactose oxidase-Schiff reaction as an early detection biomarker for colorectal cancer: comparison to fecal occult stool blood test. Cancer Biomark, 2010-2011;8(2):109-12.
  86. Acheson LS, Wang C, Zyzanski SJ, Lynn A, Ruffin MT 4th, Gramling R, Rubinstein WS, Oʼneill SM, Nease DE Jr; for the Family HealthwareTM Impact Trial (FHITr) Group. Family history and perceptions about risk and prevention for chronic diseases in primary care: a report from the Family HealthwareTM Impact Trial. Genet Med, 2010;12(4):212-8.
  87. Djuric Z, Ellsworth JS, Ren J, Sen A, Ruffin MT 4th. A randomized feasibility trial of brief telephone counseling to increase fruit and vegetable intakes. Prev Med, 2010;50(5-6):265-71.
  88. McAlearney AS, Song PH, Rhoda DA, Tatum C, Lemeshow S, Ruffin M, Harrop JP, Paskett ED. Ohio Appalachian women's perceptions of the cost of cervical cancer screening. Cancer, 2010;116(20):4727-34.
  89. Dempsey A, Cohn L, Dalton V, Ruffin M. Worsening disparities in HPV vaccine utilization among 19-26 year old women. Vaccine, 2011;29(3):528-34.
  90. Carlos RC, Dempsey AF, Ruffin MT 4th, Patel DA, Straus CM, Kure A, Dalton VK. Feasibility of using maternal cancer screening visits to identify adolescent girls eligible for HPV vaccination. J Womens Health (Larchmt) , 2010;19(12):2271-5.
  91. Zick SM, Ruffin MT, Djuric Z, Normolle D, Brenner DE. Quantitation of 6-, 8- and 10-Gingerols and 6-Shogaol in human plasma by high-performance liquid chromatography with electrochemical detection. Int J Biomed Sci, 2010;6(3):233-40.
  92. Rubinstein WS, OʼNeill SM, Rothrock N, Starzyk EJ, Beaumont JL, Acheson LS, Wang C, Gramling R, Galliher JM, Ruffin MT 4th. Components of family history associated with women's disease perceptions for cancer: A report from the Family Healthware™ Impact Trial. Genet Med, 2011;13(1):52-62.
  93. Ruffin MT 4th, Nease DE Jr, Sen A, Pace WD, Wang C, Acheson LS, Rubinstein WS, O'Neill S, Gramling R; for The Family History Impact Trial (FHITr) Group. Effect of preventive messages tailored to family history on health behaviors: The Family Healthware Impact Trial. Ann Fam Med, 2011;9(1):3-11.
  94. Patel DA, Unger ER, Walline H, Opipari AW, Lee DR, Flowers LC, Ruffin MT. Lack of HPV 16 and 18 detection in serum of colposcopy clinic patients. J Clin Virol, 2011;50(4):342-4.
  95. Carlos RC, Dempsey AF, Resnicow K, Ruffin M, Patel DA, Straus CM, Vanessa K D. Maternal characteristics that predict a preference for mandatory adolescent HPV vaccination. Hum Vaccin, 2011;7(2).
  96. Lin Z, Simeone D, Anderson MA, Brand R, Xie X, Shedden K, Ruffin MT, Lubman DM. A mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. J Proteome Res, 2011;10(5):2602-11.
  97. Owens KM, Marvin ML, Gelehrter TD, Ruffin MT 4th, Uhlmann WR. Clinical use of the Surgeon General's "My Family Health Portrait" (MFHP) Tool: opinions of future health care providers. J Genet Couns, 2011;20(5):510-25.
  98. Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, Saintigny P, Vollmer RT, Polascik TJ, Snyder DC, Ruffin MT, Yan S, Dewhirst MW, Kunnamakkara AB, Aggarwal BB, Demark-Wahnefried W. Effect of low-fat diet on plasma levels of NF-{kappa}B-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila), 2011;4(10):1590-8.
  99. Ruffin MT 4th, Nease DE Jr. Using patient monetary incentives and electronically derived patient lists to recruit patients to a clinical trial. J Am Board Fam Med, 2011;24(5):569-75.
  100. Zick SM, Turgeon DK, Vareed SK, Ruffin MT, Litzinger AJ, Wright BD, Alrawi S, Normolle DP, Djuric Z, Brenner DE. Phase II study of the effects of ginger root extract on eicosanoids in colon mucosa in people at normal risk for colorectal cancer. Cancer Prev Res (Phila), 2011;4(11):1929-37.
  101. Gargano JW, Nisenbaum R, Lee DR, Ruffin MT, Steinau M, Horowitz IR, Flowers LC, Tadros TS, Birdsong G, Unger ER. Age-group differences in human papillomavirus types and cofactors for cervical intraepithelial neoplasia 3 among women referred to colposcopy. Cancer Epidemiol Biomarkers Prev, 2012;21(1):111-21.
  102. Rubinstein WS, Acheson LS, Oʼneill SM, Ruffin MT 4th, Wang C, Beaumont JL, Rothrock N; for the Family Healthware Impact Trial (FHITr) Group. Clinical utility of family history for cancer screening and referral in primary care: A report from the Family Healthware Impact Trial. Genet Med, 2011;13(11):956-65.
  103. Dorman JS, Valdez R, Liu T, Wang C, Acheson LS, Ruffin M, Khoury M, Rubinstein W. Health beliefs among individuals at increased familial risk for type 2 diabetes: implications for prevention diabetes research and clinical practice. Diabetes Res Clin Pract, 2012;96(2):156-62.
  104. Sadigh G, Dempsey AF, Ruffin M, Resnicow K, Carlos RC. National patterns in human papillomavirus vaccination: An analysis of the National Survey of Family Growth. Hum Vaccin Immunother, 2012;8(2):234-42.
  105. Yurgelun MB, Goel A, Hornick JL, Sen A, Turgeon DK, Ruffin MT 4th, Marcon NE, Baron JA, Bresalier RS, Syngal S, Brenner DE, Boland CR, Stoffel EM. Microsatellite instability and DNA mismatch repair protein deficiency in lynch syndrome colorectal polyps. Cancer Prev Res (Phila), 2012;5(4):574-82.
  106. Djuric Z, Ruffin MT 4th, Rapai ME, Cornellier ML, Ren J, Ferreri TG, Askew L, Sen A, Brenner DE, Turgeon DK. A Mediterranean dietary intervention in persons at high risk of colon cancer: Recruitment and retention to an intensive study requiring biopsies. Contemp Clin Trials, 2012;33(5):881-8.
  107. Patel DA, Rozek LS, Colacino JA, Van Zomeren-Dohm A, Ruffin MT, Unger ER, Dolinoy DC, Swan DC, Onyekwuluje J, Degraffinreid CR, Paskett ED. Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia. J Virol Methods, 2012;184(1-2):84-92.
  108. Ruffin, MT, IV, Hade EM, Gorsline MR, DeGraffinreid CR, Katz ML, Kobrin SC, Paskett ED. Human papillomavirus vaccine knowledge and hypothetical acceptance among women in Appalachia Ohio Vaccine. Vaccine, 2012;30(36):5349-57.
  109. Wang C, Sen A, Ruffin MT, IV, Nease DE, Jr., Gramling R, Acheson LS, O’Neill SM, Rubinstein WS; for the Family HealthwareTM Impact Trial (FHITr) Group. Family history assessment: impact on disease risk perceptions. Am J Prev Med, 2012;43(4):392-8.
  110. Lin Z, Lo A, Simeone DM, Ruffin MT, Lubman DM. An n-glycosylation analysis of human alpha-2-macroglobulin using an integrated approach. J Proteomics Bioinform, 2012;5:127-34.
  111. Kelly KM, Ferketich AK, Ruffin MT IV, Tatum C, Paskett ED. Perceived risk of cervical cancer in Appalachian women. Am J Health Behav, 2012;36(6):849-59.
  112. Azrad M, Zhang K, Vollmer RT, Madden J, Polascik TJ, Snyder DC, Ruffin MT, Moul JW, Brenner D, Hardy RW, Demark-Wahnefried W. Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: A relationship which may depend on genetic variation in ALA metabolism. PLoS One, 2012;7(12):e53104.
  113. Citronberg J, Bostick RM, Ahearn TU, Turgeon DK, Ruffin MT, Djuric Z, Sen A, Brenner DE, Zick SM. Effects of ginger supplementation on cell cycle biomarkers in the normal-appearing colonic mucosa: results from a pilot, randomized, controlled trial. Cancer Prev Res (Phila), 2013;6(4):271-81.
  114. Jimbo M, Rana GK, Hawley S, Holmes-Rovner M, Kelly-Blake K, Nease DE Jr, Ruffin MT 4th. What is lacking in current decision aids on cancer screening? CA Cancer J Clin, 2013;63(3):193-214.
  115. Azrad M, Vollmer RT, Madden J, Dewhirst M, Polascik TJ, Snyder DC, Ruffin MT, Moul JW, Brenner DE, Demark-Wahnefried W. Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. J Med Food, 2013;16(4):357-60.
  116. Sen A, Ren J, Ruffin MT, Turgeon DK, Brenner DE, Sidahmed E, Rapai ME, Cornellier ML, Djuric Z. Relationships between serum and colon concentrations of carotenoids and fatty acids in randomized dietary intervention trial. Cancer Prev Res (Phila), 2013:6(6):558-65.
  117. Nie S, Lo A, Zhu J, Wu J, Ruffin MT, Lubman DM. Isobaric protein-level labeling strategy for serum glycoprotein quantification analysis by liquid chromatography-tandem mass spectrometry. Anal Chem, 2013;85(11):5353-7.
  118. Post DM, Gehlert S, Hade EM, Reiter PL, Ruffin M, Paskett ED. Depression and SES in women from Appalachia. Journal of Rural Mental Health, 2013;37(1):2-15.
  119. Jiang Y, Turgeon DK, Wright BD, Sidahmed E, Ruffin MT, Brenner DE, Sen A, Zick SM. Effect of ginger root on cyclooxygenase-1 and 15-hydroxyprostaglandin dehydrogenase expression in colonic mucosa of humans at normal and increased risk for colorectal cancer. Eur J Cancer Prev, 2013;22(5):455-60.
  120. Reiter PL, Katz ML, Ruffin MT, Hade EM, DeGraffenreid CR, Patel DA, Paskett ED, Unger ER. HPV prevalence among women from Appalachia: results from the CARE Project. PLOS ONE, 2013;8(10).
  121. de la Cruz MD, Young AP, Ruffin MT IV. HPV testing for normal cervical cytology in low-risk women age 30-65 years by family physicians. J Am Board Fam Med 2013;26(6):720-7.
  122. Jimbo M, Kelly-Blake K, Sen A, Hawley ST, Ruffin IV MT. Decision Aid to Technologically Enhance Shared decision making (DATES): study protocol for a randomized controlled trial. Trials 2013;14(1):381.
  123. Lin Z, Yin H, Lo A, Ruffin MT, Anderson MA, Simeone DM, Lubman DM. Label-free relative quantification of alpha-2-macroglobulin site-specific core-fucosylation in pancreatic cancer by LC-MS/MS. Electrophoresis 2013 Nov 27. [Epub ahead of print]
  124. Katz ML, Oldach BR, Goodwin J, Reiter PL, Ruffin MT 4th, Paskett ED. Development and initial feedback about a human papillomavirus (hpv) vaccine comic book for adolescents. J Cancer Educ 2014 Jan 15. [Epub ahead of print]
  125. de la Cruz MD, Young AP, Ruffin MT IV. Diagnosis and management of pancreatic cancer. Am Fam Physician, in press.
Book Chapters
  1. Smith MA, Ruffin MT. Obstetrics, (in) Saunders' Review of Family Practice, (eds) Bope E, Cass AR, Hagen M; W. B. Saunders Co., Philadelphia, 1993.
  2. Smith MA, Ruffin MT. Antepartum Care, (in) Conn's Current Therapy, (ed) Rakel RE; W. B. Saunders Co., Philadelphia, 1993.
  3. Rock CL, Coulston AM, Ruffin MT. Diet Therapy, (in) Harrison's Principles of Internal Medicine. 14th Edition (eds) Fauci AS, Braunwald E, Isselbacker KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL; McGraw-Hill, New York, 1998.
  4. Krishnan K, Ruffin MT, Brenner DE. Aspirin and Other Prostaglandin Inhibitors for the Prevention of Colon Cancer, (in) Infusion Chemotherapy-Irradiation Interactions, (eds) Rosenthal CJ, Rotman M; Elsevier, Amsterdam, 1998.
  5. Paskett ED, Wewers ME, Ruffin MT IV. Educational Strategies for the Prevention of Cervical Cancer, (in) Cervical Cancer: From Etiology to Prevention, (eds) Rohan TE, Shah KV; Kluwer Academic Publishers: The Netherlands, 2004.
  6. Shureiqi, Reddy, Ruffin, Brenner. Prevention and Screening Principles Relevant to Gastrointestinal Malignancies, (in) Gastrointestinal Oncology, (eds) Abbruzzese, Evans, Willett and Feoglio-Preiser; Oxford University Press, New York, 2003.
  7. Ruffin MT IV, Rock CL. Human Papillomavirus Infection in Men and Women: The Impact of Nutrition on Cervical Cancer, (in) Principles of Gender-Specific Medicine, (ed) Legato M; Elsevier Academic Press, San Diego, 2004.
  8. Nease DE, Stoffel E, Turgeon DK, Ruffin MT, IV. Colorectal Cancer Screening. Clin Fam Pract, 2004:6(3):693-707.
  9. Unger ER, Ruffin MT, IV, Diaz-Arrastia C. Human Papillomaviruses, (in) Clinical Gynecology, (eds) Bieber EJ, Sanfilippo JS, Horowitz IR; Churchill Livingstone, Canada, 2006.
  10. Young EP, de la Cruz MSD, Ruffin MT. Clinical Utility of HPV Testing in Cervical Cancer Screening (in) Handbook of Human Papillomavirus: Prevalence, Detection and Management, (ed) Smith HB; Nova Sciences Publishers, Inc.: ebook, 2013:213-40.

Downloads

Dr. Mack Ruffin IV's CV